Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.40 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29837928 | 0.85 | USP2 (0.79) | USP2HTTPLA2G2CLPAR5SPHK1 | |
| SCHEMBL8619644 | 0.85 | USP2 (0.79) | USP2HTTPLA2G2CLPAR5SPHK1 | |
| SCHEMBL8620507 | 0.85 | USP2 (0.79) | USP2HTTPLA2G2CLPAR5SPHK1 | |
| SCHEMBL8622815 | 0.85 | USP2 (0.79) | USP2HTTPLA2G2CLPAR5SPHK1 | |
| SCHEMBL8622282 | 0.85 | USP2 (0.79) | USP2HTTPLA2G2CLPAR5SPHK1 | |
| SCHEMBL6230528 | 0.85 | USP2 (0.79) | USP2HTTPLA2G2CLPAR5SPHK1 | |
| SCHEMBL26699142 | 0.84 | USP2 (0.48) | USP2HTTPLA2G2CLMNACYP1A2 | |
| SCHEMBL11042040 | 0.83 | USP2 (0.75) | USP2HTTPLA2G2CLPAR5SPHK1 | |
| SCHEMBL31077567 | 0.83 | USP2 (0.59) | USP2HTTPLA2G2CLPAR5SPHK1 | |
| SCHEMBL22067854 | 0.83 | USP2 (0.59) | USP2HTTPLA2G2CLPAR5SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363599-B1 | MILD MOISTURIZING LIQUIDS WITH SOAP-LIKE RINSE FEEL | UNILEVER PLC (GB) | 2012-12-19 | — | — | EP | claimed |
| EP-3824878-B1 | ABUSE RESISTANT CAPSULE | SCHERER TECHNOLOGIES LLC R P (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12133922-B2 | Abuse resistant capsule | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2024-11-05 | — | — | US | disclosed |
| US-20240350418-A1 | LIPID-BASED COMPOSITION FOR ORAL ADMINISTRATION OF BRADYKININ B2-RECEPTOR ANTAGONISTS | ANALYTICON DISCOVERY GMBH (DE) | 2024-10-24 | — | — | US | disclosed |
| WO-2024201560-A1 | IODINE CONTAINING COLLOIDAL LIQUID COMPOSITION | ME.LINK CO., LTD. (JP) | 2024-10-03 | — | — | WO | disclosed |
| CN-118076342-A | Lipid-based compositions for oral administration of bradykinin B2 receptor antagonists | 法瓦里斯有限责任公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4203919-B1 | LIPID-BASED COMPOSITION FOR ORAL ADMINISTRATION OF BRADYKININ B2-RECEPTOR ANTAGONISTS | PHARVARIS GMBH (CH) | 2024-01-31 | — | — | EP | disclosed |
| EP-4203919-A1 | LIPID-BASED COMPOSITION FOR ORAL ADMINISTRATION OF BRADYKININ B2-RECEPTOR ANTAGONISTS | Pharvaris GmbH (CH) | 2023-07-05 | — | — | EP | disclosed |
| WO-2023012322-A1 | LIPID-BASED COMPOSITION FOR ORAL ADMINISTRATION OF BRADYKININ B2-RECEPTOR ANTAGONISTS | PHARVARIS GMBH (CH) | 2023-02-09 | — | — | WO | disclosed |
| US-20220362160-A1 | ABUSE RESISTANT CAPSULE | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2022-11-17 | — | — | US | disclosed |
| US-20030054019-A1 | Wet-skin treatment compositions | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2003-03-20 | — | — | US | disclosed |
| US-20030049282-A1 | Method of enhanced moisture or reduced drying using wet-skin treatment compositions | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2003-03-13 | — | — | US | disclosed |
| US-6521573-B2 | Mixture of hydrophobic polymer and lotion oil | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2003-02-18 | — | — | US | disclosed |
| WO-2002092043-A2 | WET-SKIN TREATMENT COMPOSITIONS | UNILEVER PLC (GB) | 2002-11-21 | — | — | WO | disclosed |
| US-20020165103-A1 | PERSONAL CLEANSING COMPOSITIONS PROVIDING RINSABILITY AND DRAGGY WET SKIN FEEL | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2002-11-07 | — | — | US | disclosed |
| WO-2002074252-A2 | MILD MOISTURIZING LIQUIDS WITH SOAP-LIKE RINSE FEEL | UNILEVER PLC (GB) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002067888-A1 | PERSONAL WASH COMPOSITIONS CONTAINING PARTICLE-IN-OIL DISPERSION | UNILEVER PLC (GB) | 2002-09-06 | — | — | WO | disclosed |
| WO-2002067892-A2 | PROCESS FOR MAKING MILD MOISTURIZING LIQUIDS CONTAINING LARGE OIL DROPLET | UNILEVER PLC (GB) | 2002-09-06 | — | — | WO | disclosed |
| US-6395691-B1 | MIXTURE CONTAINING SURFACTANTS | UNILEVER HOME & PERSONAL CARE USA DIVISION OF CONOPCO, INC. | 2002-05-28 | — | — | US | disclosed |
| US-6395690-B1 | MIXING SURFACTANT, OIL AND POLYMER | UNILEVER HOME & PERSONAL CARE USA DIVISION OF CONOPCO, INC. | 2002-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240350418-A1 | LIPID-BASED COMPOSITION FOR ORAL ADMINISTRATION OF BRADYKININ B2-RECEPTOR ANTAGONISTS | BDKRB2, BDKRB1, LTB4R2 | USP2 2015/4885HTT 3939/4885PLA2G2C 383/4885 |
| US-20020165103-A1 | PERSONAL CLEANSING COMPOSITIONS PROVIDING RINSABILITY AND DRAGGY WET SKIN FEEL | DSG1, CUTA, SMURF1 | USP2 518/4885HTT 1541/4885PLA2G2C 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.